Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
1,300 | 1,300 | 15,257,530 | 1,617 | A composition and method of treating patients diagnosed with NAFLD is disclosed. The composition contains n-3 polyunsaturated fatty acids (PUFAs) for treatment of NAFLD patients, wherein the amount of PCB 153 in the composition has been minimized. The composition is administered to a patient in a sufficient amount and ... | 1. A method of treating a patient diagnosed with non-alcoholic fatty liver disease (NAFLD) comprising administering an n3 polyunsaturated fatty acids (n3 PUFAs) composition to the patient in a sufficient amount to increase a level of n3 PUFAs or to correct a deficiency of n3 PUFAs in the blood of the patient, wherein t... | A composition and method of treating patients diagnosed with NAFLD is disclosed. The composition contains n-3 polyunsaturated fatty acids (PUFAs) for treatment of NAFLD patients, wherein the amount of PCB 153 in the composition has been minimized. The composition is administered to a patient in a sufficient amount and ... | 1,600 |
1,301 | 1,301 | 16,178,788 | 1,612 | An oral care composition containing a source of stannous ions, a source of fluoride ions and an insoluble source of zinc ions, such as zinc oxide. The composition contains an amount of citric acid sufficient to increase the level of soluble zinc ions. | 1. An oral care composition comprising in a single phase:
(a) an orally acceptable vehicle; (b) a source of fluoride ions; (c) a source of stannous ions; (d) an insoluble source of zinc ions; (e) a buffering system comprising citric acid wherein the amount of citric acid is 0.5-4% by weight of the composition, and wher... | An oral care composition containing a source of stannous ions, a source of fluoride ions and an insoluble source of zinc ions, such as zinc oxide. The composition contains an amount of citric acid sufficient to increase the level of soluble zinc ions.1. An oral care composition comprising in a single phase:
(a) an oral... | 1,600 |
1,302 | 1,302 | 14,198,061 | 1,617 | The disclosure provides for methods of repelling, directing, altering the behavior, and controlling an insect by utilizing a compound or composition described herein. The disclosure also provides for methods of promoting the health of an insect by repelling a pest that preys on insect and/or by providing an antibiotic ... | 1. A method of repelling, controlling, and/or directing an insect from a seed, plant part, or plant comprising
a) treating a seed, plant part, or plant with at least one compound of Formula (I)-(IX) selected from the group consisting of:
in which,
R1 and R2 are independently selected from methyl, ethyl, pro... | The disclosure provides for methods of repelling, directing, altering the behavior, and controlling an insect by utilizing a compound or composition described herein. The disclosure also provides for methods of promoting the health of an insect by repelling a pest that preys on insect and/or by providing an antibiotic ... | 1,600 |
1,303 | 1,303 | 16,033,528 | 1,619 | The present invention provides sunscreen composition comprising a hydrophobically modified polyurethane, a viscosity increasing polymer, and glyceryl stearate. This composition has surprisingly light aesthetics while providing excellent UV protection. | 1. A sunscreen composition comprising:
(a) at least about 10 weight percent of one or more UV filters; (b) about 0.55 to about 1 weight percent of a hydrophobically modified polyurethane; (c) about 0.1 to about 0.6 weight percent of a viscosity increasing polymer selected from the group consisting of taurate copolymers... | The present invention provides sunscreen composition comprising a hydrophobically modified polyurethane, a viscosity increasing polymer, and glyceryl stearate. This composition has surprisingly light aesthetics while providing excellent UV protection.1. A sunscreen composition comprising:
(a) at least about 10 weight p... | 1,600 |
1,304 | 1,304 | 14,758,457 | 1,617 | A microgranule preparation for oral administration which is characterized in that an inert core coated with a drug layer is mixed with sugar or sugar alcohol is provided. | 1. A microgranule preparation for oral administration, which is characterized in that an inert core coated with a drug layer is mixed with sugar or sugar alcohol. 2. The microgranule preparation according to claim 1, wherein the inert core is sugar or sugar alcohol. 3. The microgranule preparation according to claim 1,... | A microgranule preparation for oral administration which is characterized in that an inert core coated with a drug layer is mixed with sugar or sugar alcohol is provided.1. A microgranule preparation for oral administration, which is characterized in that an inert core coated with a drug layer is mixed with sugar or su... | 1,600 |
1,305 | 1,305 | 15,400,505 | 1,615 | A method of economically producing stable and bio-available glutathione comprising immersing glutathione particles in an edible oil preferably selected from at least one of almond, coconut, grapeseed and olive; reducing the average size of glutathione particles to not more than 50 microns and preferably 1 or less; and ... | 1. A method of economically producing stable and bio-available glutathione comprising:
a. immersing glutathione particles in an edible oil; b. reducing the average size of glutathione particles to not more than 50 microns; and c. adding a de-agglomeration agent. 2. The method of claim 1 further comprising:
a. the oil s... | A method of economically producing stable and bio-available glutathione comprising immersing glutathione particles in an edible oil preferably selected from at least one of almond, coconut, grapeseed and olive; reducing the average size of glutathione particles to not more than 50 microns and preferably 1 or less; and ... | 1,600 |
1,306 | 1,306 | 14,782,879 | 1,623 | The present invention relates to a method of deoxygenating tall oil pitch, yielding aliphatic and aromatic hydrocarbons. The invention even comprises turning the aliphates into polymerizable olefins by steam cracking, and turning the aromates into polymerizable terephthalic acid by oxygenation and, as necessary, rearra... | 1. A method of deoxygenating tall oil pitch, wherein
tall oil pitch, which contains a share of fatty and resin acids and/or their derivatives, is heated to a temperature sufficient to turn it liquid; said liquid is fed into a catalyst bed, to bring it into contact with hydrogen and one or more catalysts in said catalys... | The present invention relates to a method of deoxygenating tall oil pitch, yielding aliphatic and aromatic hydrocarbons. The invention even comprises turning the aliphates into polymerizable olefins by steam cracking, and turning the aromates into polymerizable terephthalic acid by oxygenation and, as necessary, rearra... | 1,600 |
1,307 | 1,307 | 14,894,473 | 1,623 | The present invention relates to a process for producing a low endotoxin alkali chitosan, chitin, chitosan derivative or chitin derivative, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting ... | 1. A process for producing a low endotoxin alkali chitosan, chitin or a derivative thereof, the process comprising the steps of:
(a) contacting chitosan, chitin, a chitosan derivative or a chitin derivative with an alkali solution having a concentration of less than 0.25M to form a mixture; and (b) leaving the mixture ... | The present invention relates to a process for producing a low endotoxin alkali chitosan, chitin, chitosan derivative or chitin derivative, and also to a process for producing low endotoxin neutral chitosan, chitosan salt and chitosan derivatives, and to the products of such processes. The process comprises contacting ... | 1,600 |
1,308 | 1,308 | 15,494,160 | 1,617 | Compositions including a quaternary ammonium compound (such as alkyl dimethyl benzyl ammonium chloride) and a linear monocarboxylic fatty acid are disclosed. The compositions are useful to inhibit the growth of an organism or to remove or reduce a stain resulting from the growth of an organism. Such compositions are us... | 1. A composition comprising:
a quaternary ammonium compound that comprises an alkyl chain; and a linear monocarboxylic fatty acid. 2. The composition of claim 1, wherein the quaternary ammonium compound comprises one or more of alkyl dimethyl benzyl ammonium chloride (“ADBAC”), alkyl dimethyl ethyl benzyl ammonium chlo... | Compositions including a quaternary ammonium compound (such as alkyl dimethyl benzyl ammonium chloride) and a linear monocarboxylic fatty acid are disclosed. The compositions are useful to inhibit the growth of an organism or to remove or reduce a stain resulting from the growth of an organism. Such compositions are us... | 1,600 |
1,309 | 1,309 | 16,035,762 | 1,612 | Compositions comprising UV blocking agents, a film forming polymer containing acid groups and a neutralizing agent; compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent. | 1-40. (canceled) 41. A sprayable anhydrous sunscreen composition comprising
at least one UV absorbing active ingredient, a film forming polymer containing a plurality of acid groups, which film forming polymer is an Acrylates/Octylacrylamide Copolymer, and a volatile solvent, wherein the film forming polymer is present... | Compositions comprising UV blocking agents, a film forming polymer containing acid groups and a neutralizing agent; compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent.1-40. (canceled) 41. A sprayabl... | 1,600 |
1,310 | 1,310 | 15,206,595 | 1,619 | A hair straightening and/or hair relaxing method comprising: applying a hair care composition to hair, wherein the composition comprises a sugar, a buffering agent and a cosmetically acceptable carrier; and wherein, where the composition is heated to a temperature of at least 100° C., the composition comprises from abo... | 1. A composition for straightening hair comprising:
from about 12% to about 18% reducing sugar, by weight of the formulation, wherein the reducing sugar is selected from the group consisting of: arabinose, ribose, and mixtures thereof; a buffering agent; a cosmetically acceptable carrier; a conditioning agent being the... | A hair straightening and/or hair relaxing method comprising: applying a hair care composition to hair, wherein the composition comprises a sugar, a buffering agent and a cosmetically acceptable carrier; and wherein, where the composition is heated to a temperature of at least 100° C., the composition comprises from abo... | 1,600 |
1,311 | 1,311 | 15,648,240 | 1,639 | The present disclosure is directed to a single-end sequencing method for improved detection of genomic rearrangements such as deletions, insertions, inversions, and translocations that are present in a polynucleotide. A first priming event allows for sequencing of a target sequence, and a second priming event on an ada... | 1. A method of preparing a polynucleotide for sequencing by attaching a target-specific barcode, the method comprising:
amplifying a polynucleotide with a first amplification primer and a second amplification primer, wherein the first amplification primer hybridizes to a first priming site of the polynucleotide, and th... | The present disclosure is directed to a single-end sequencing method for improved detection of genomic rearrangements such as deletions, insertions, inversions, and translocations that are present in a polynucleotide. A first priming event allows for sequencing of a target sequence, and a second priming event on an ada... | 1,600 |
1,312 | 1,312 | 14,210,118 | 1,619 | According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additiv... | 1. A medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additive which is hydrolytically stable; wherein at least a ... | According to the invention there is provided inter alia a medical device for delivering a therapeutic agent to a tissue, the device having a solid surfactant-free particulate coating layer applied to a surface of the device, the coating layer comprising a therapeutic agent and at least one non-polymeric organic additiv... | 1,600 |
1,313 | 1,313 | 13,847,453 | 1,613 | Antimicrobial skin prep solutions of the invention comprise: a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount o... | 1. An antimicrobial skin prep solution comprising:
a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount of at least... | Antimicrobial skin prep solutions of the invention comprise: a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount o... | 1,600 |
1,314 | 1,314 | 12,527,417 | 1,635 | The present invention provides 5′-substituted-2′-F nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In one preferred embodiment the nucleoside analogs have either (R) or (5)-chirality at the 5′-position. These nucleoside analogs are expected to be useful for enhancing properties of oligo... | 1. A compound having the formula:
wherein:
Bx is an optionally modified heterocyclic base moiety;
T1 is H or a hydroxyl protecting group;
T2 is H, a hydroxyl protecting group or a reactive phosphorus group;
Z is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, substituted C1-C6 alkyl, substituted C2-C6 alkenyl or ... | The present invention provides 5′-substituted-2′-F nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In one preferred embodiment the nucleoside analogs have either (R) or (5)-chirality at the 5′-position. These nucleoside analogs are expected to be useful for enhancing properties of oligo... | 1,600 |
1,315 | 1,315 | 13,860,897 | 1,644 | An anti-MHC removal device includes a serologically active, soluble MHC moiety covalently coupled to a solid support. Methods of production include covalently coupling the serologically active, soluble MHC moiety to the solid support. Methods of use of the anti-MHC removal device include contacting a biological sample ... | 1. An anti-MHC removal device, comprising:
a solid support; a serologically active, soluble MHC moiety covalently coupled to the solid support and disposed on a surface of the anti-MHC removal device, the MHC moiety capable of interacting with a sample brought into contact with the surface of the device having the sero... | An anti-MHC removal device includes a serologically active, soluble MHC moiety covalently coupled to a solid support. Methods of production include covalently coupling the serologically active, soluble MHC moiety to the solid support. Methods of use of the anti-MHC removal device include contacting a biological sample ... | 1,600 |
1,316 | 1,316 | 15,525,173 | 1,627 | A nanosuspension comprising (a) a pharmaceutical active ingredient or nutraceutical active ingredient having low solubility; (b) at least one alginate selected from the group consisting of (i) sodium alginate having a viscosity of 100 mPa·s or less in a 1% solution in water at 20° C. and (ii) potassium alginate; and (c... | 1. A nanosuspension comprising (a) a pharmaceutical active ingredient or nutraceutical active ingredient having low solubility; (b) at least one alginate selected from the group consisting of (i) sodium alginate having a viscosity of 100 mPa·s or less in a 1% solution in water at 20° C. and (ii) potassium alginate; and... | A nanosuspension comprising (a) a pharmaceutical active ingredient or nutraceutical active ingredient having low solubility; (b) at least one alginate selected from the group consisting of (i) sodium alginate having a viscosity of 100 mPa·s or less in a 1% solution in water at 20° C. and (ii) potassium alginate; and (c... | 1,600 |
1,317 | 1,317 | 14,240,617 | 1,615 | An adhesive composition comprising silicone adhesives and one or more absorbent fillers such as hydrocolloids is disclosed. The adhesive composition is particularly well suited for use in negative pressure wound therapies. | 1. An adhesive composition comprising:
a polysiloxane adhesive; and one or more absorbent fillers dispersed in the polysiloxane adhesive. 2. The adhesive of claim 1 wherein the polysiloxane adhesive is a one-part adhesive and at least partially crosslinked. 3. The adhesive of claim 1 wherein the polysiloxane adhesive i... | An adhesive composition comprising silicone adhesives and one or more absorbent fillers such as hydrocolloids is disclosed. The adhesive composition is particularly well suited for use in negative pressure wound therapies.1. An adhesive composition comprising:
a polysiloxane adhesive; and one or more absorbent fillers ... | 1,600 |
1,318 | 1,318 | 15,767,493 | 1,613 | A method for protecting a plant from an arthropod may include applying an amount of a repellant composition including diatomaceous earth to a plant. According to some aspects, the repellent composition may render the plant unpalatable to the arthropod, resulting in death of the arthropod by starvation. A method for pro... | 1. A method for protecting a plant from an arthropod, the method comprising:
applying an amount of a repellant composition comprising diatomaceous earth to a plant, wherein the repellent composition renders the plant unpalatable to the arthropod, resulting in death of the arthropod by starvation. 2. The method of claim... | A method for protecting a plant from an arthropod may include applying an amount of a repellant composition including diatomaceous earth to a plant. According to some aspects, the repellent composition may render the plant unpalatable to the arthropod, resulting in death of the arthropod by starvation. A method for pro... | 1,600 |
1,319 | 1,319 | 16,451,625 | 1,615 | An extended release formulation is provided for use in a method for the treatment of Central Precocious Puberty (CPP) in pediatric patients 2 years of age or older. The extended release formulation comprises leuprolide or a pharmaceutically acceptable salt thereof, a biodegradable polymer, and a biocompatible organic s... | 1. A method of treating pediatric patients 2 years of age and older with central precocious puberty (CPP), the method comprising administering to a pediatric patient who has CPP, once per about six months, a subcutaneous injection of an extended release composition comprising:
a. an organic solvent; b. leuprolide or a ... | An extended release formulation is provided for use in a method for the treatment of Central Precocious Puberty (CPP) in pediatric patients 2 years of age or older. The extended release formulation comprises leuprolide or a pharmaceutically acceptable salt thereof, a biodegradable polymer, and a biocompatible organic s... | 1,600 |
1,320 | 1,320 | 14,848,390 | 1,662 | The invention relates to methods and compositions for identifying and selecting maize plants with enhanced resistance to northern leaf blight. Maize plants generated by the methods of the invention are also a feature of the invention. | 1. A recombinant DNA construct comprising an isolated polynucleotide operably linked to at least one regulatory sequence, wherein said isolated polynucleotide comprises:
a. at least one nucleotide sequence encoding a polypeptide capable of conferring or enhancing resistance to northern leaf blight, wherein the polypept... | The invention relates to methods and compositions for identifying and selecting maize plants with enhanced resistance to northern leaf blight. Maize plants generated by the methods of the invention are also a feature of the invention.1. A recombinant DNA construct comprising an isolated polynucleotide operably linked t... | 1,600 |
1,321 | 1,321 | 15,035,161 | 1,632 | The present invention relates to a pharmaceutical composition comprising, as active substance, Saccharomyces boulardii yeast cells, for use for reducing body fat in an individual. | 1. A method for reducing body fat in an individual, comprising administering an effective amount of a pharmaceutical composition comprising, as active substance, Saccharomyces boulardii yeast cells to the individual. 2. The method according to claim 1, wherein the individual has an excess body fat. 3. The method accord... | The present invention relates to a pharmaceutical composition comprising, as active substance, Saccharomyces boulardii yeast cells, for use for reducing body fat in an individual.1. A method for reducing body fat in an individual, comprising administering an effective amount of a pharmaceutical composition comprising... | 1,600 |
1,322 | 1,322 | 15,678,337 | 1,653 | An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid. The fiber component typically will have short fiber lengths, so as to avoid forming entangled masses or clumps when mixed with a fluid. In an embodiment, the fiber material is nati... | 1)-16) (canceled) 17) A method of preparing an implantable tissue scaffold comprising the steps of:
a. introducing into a mold a composition comprising at least one blood fraction and a collagen fiber component; and b. allowing the composition to set to form a fiber reinforced clot having the shape of the mold, and c. ... | An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid. The fiber component typically will have short fiber lengths, so as to avoid forming entangled masses or clumps when mixed with a fluid. In an embodiment, the fiber material is nati... | 1,600 |
1,323 | 1,323 | 15,720,373 | 1,633 | Methods for the isolation of CD271 + stem cell populations are important in the prevention or treatment of cardiovascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's ... | 1. A method of preventing or treating a cardiovascular disease or disorder in a patient comprising:
isolating CD271+ mesenchymal stem cell precursors from bone marrow of a subject, wherein the subject is the same or different than the patient; administering to the patient a therapeutically effective amount of isolated ... | Methods for the isolation of CD271 + stem cell populations are important in the prevention or treatment of cardiovascular diseases and repair of cardiac tissue. The methods are applicable to stem cells from different sources and can be used to treat or prevent diseases or repair of tissues elsewhere in the organism's ... | 1,600 |
1,324 | 1,324 | 14,007,549 | 1,628 | The invention relates to a composition comprising, in a physiologically acceptable oily medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<δ a <7 and 14<δ d <22. Use for caring for, making up and cleansing keratin materials. | 1. Composition comprising, in a physiologically acceptable oily medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and an organic solvent with solubility parameters in the Hansen solubility space such that 4.5<δa<7 and 14<δd<22. 2. Composition according to claim 1, wherein the organic solvent is chosen from isopropyl N-la... | The invention relates to a composition comprising, in a physiologically acceptable oily medium, 4-(3-ethoxy-4-hydroxyphenyl)-2-butanone and a solvent with solubility parameters in the Hansen solubility space such that 4.5<δ a <7 and 14<δ d <22. Use for caring for, making up and cleansing keratin materials.1. Compositio... | 1,600 |
1,325 | 1,325 | 16,048,004 | 1,628 | A method of improving sexual function in premenopausal women, who have low Female Sexual Function Index (FSFI) baseline of less than or equal to 25.7. The method includes providing information to premenopausal women to provide input for calculating the FSFI score and, if the score is low, providing dehydroepiandrostero... | 1. A method of improving female sexual function through dehydroepiandrosterone (DHEA) supplementation, comprising the steps of:
giving a premenopausal woman access to information for her to provide input necessary for computing a Female Sexual Function Index (FSFI) baseline; confirming that the computed FSFI baseline o... | A method of improving sexual function in premenopausal women, who have low Female Sexual Function Index (FSFI) baseline of less than or equal to 25.7. The method includes providing information to premenopausal women to provide input for calculating the FSFI score and, if the score is low, providing dehydroepiandrostero... | 1,600 |
1,326 | 1,326 | 15,463,665 | 1,645 | The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a ... | 1. An immunogenic pharmaceutical composition comprising a recombinant staphylococcal clumping factor A (ClfA), or fragment thereof comprising at least amino acid residues 221 to 531 of the fibrinogen binding region, characterized by at least one amino acid residue substitution or deletion at amino acid residue Ala254, ... | The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a ... | 1,600 |
1,327 | 1,327 | 15,641,114 | 1,653 | Aquafeed, animal feed, and other food products, as well as nutritional and pharmaceutical compounds, chemicals and biomaterials are important commodities that can be produced at commercial scale by fermentation of microorganisms. The present invention provides a method for producing these valuable multi-carbon compound... | 1. A food or feed additive product comprising:
a consortium of chemoautotrophic and photoautotrophic bacteria and heterotrophic microbes, the consortium including chemoautotrophic bacteria from the genera Cupriavidus, Methylococcus, or Rhodococcus, photoautotrophic bacteria from the genera Rhodobacter, Rhodospirillum... | Aquafeed, animal feed, and other food products, as well as nutritional and pharmaceutical compounds, chemicals and biomaterials are important commodities that can be produced at commercial scale by fermentation of microorganisms. The present invention provides a method for producing these valuable multi-carbon compound... | 1,600 |
1,328 | 1,328 | 15,549,877 | 1,623 | A process for preparing an ester of a cellulose ether comprises the steps of reacting a cellulose ether with a dicarboxylic acid anhydride or with a combination of a dicarboxylic acid anhydride and an aliphatic monocarboxylic acid anhydride, wherein the esterification is conducted i) in the absence of an esterification... | 1. A process for preparing an ester of a cellulose ether comprising the steps of
reacting a cellulose ether with a dicarboxylic acid anhydride or with a combination of a dicarboxylic acid anhydride and an aliphatic monocarboxylic acid anhydride, wherein the esterification is conducted
i) in the absence of an esterifica... | A process for preparing an ester of a cellulose ether comprises the steps of reacting a cellulose ether with a dicarboxylic acid anhydride or with a combination of a dicarboxylic acid anhydride and an aliphatic monocarboxylic acid anhydride, wherein the esterification is conducted i) in the absence of an esterification... | 1,600 |
1,329 | 1,329 | 14,537,057 | 1,632 | A method for producing a polyunsaturated fatty acid (PUFA) or a lipid containing a PUFA, a microbial cell containing a PUFA, and use of the microbial cell are provided. A method for producing a polyunsaturated fatty acid (PUFA) or a lipid containing a PUFA including culture of a microorganism capable of producing arach... | 1-7. (canceled) 8. A method for producing arachidonic acid (ARA) comprising cultivating Mortierella alpina by an aeration-spinner culture process in a liquid culture medium, and the method further comprising at least the following steps:
adding at least one organic acid selected from the group consisting of succinic ac... | A method for producing a polyunsaturated fatty acid (PUFA) or a lipid containing a PUFA, a microbial cell containing a PUFA, and use of the microbial cell are provided. A method for producing a polyunsaturated fatty acid (PUFA) or a lipid containing a PUFA including culture of a microorganism capable of producing arach... | 1,600 |
1,330 | 1,330 | 15,393,026 | 1,658 | The present invention relates to pharmaceutical compositions having improved stability. | 1-37. (canceled) 38. A liquid composition, comprising:
a pharmaceutically active compound selected from:
a compound having the formula (I):
wherein: n is selected from 0, 1 and 2; p is selected from 0, 1, 2, 3, 4, 5 and 6; R1 is selected from aryl optionally substituted with at least one OH, F, Cl, Br, alk... | The present invention relates to pharmaceutical compositions having improved stability.1-37. (canceled) 38. A liquid composition, comprising:
a pharmaceutically active compound selected from:
a compound having the formula (I):
wherein: n is selected from 0, 1 and 2; p is selected from 0, 1, 2, 3, 4, 5 and ... | 1,600 |
1,331 | 1,331 | 16,596,680 | 1,617 | The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue. | 1. A method of stabilising a tear film in an individual having an ocular surface inflammatory disorder including:
providing an individual having an ocular surface inflammatory disorder that is characterised by an unstable tear film, wherein the disorder is selected from dry eye and blepharitis; and providing a compound... | The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue.1. A method of stabilising a tear film in an individua... | 1,600 |
1,332 | 1,332 | 14,768,267 | 1,658 | The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal of certain undesirable impurities without adversely effecting the yield of the desired protein product. | 1. A method of selectively removing of a protein from a sample comprising at least two proteins, the method comprising the steps of:
(a) providing a sample comprising at least two proteins, one of which is to be selectively removed; (b) adjusting the solution pH of the sample, such that the pH is within 2.0 pH units of... | The present invention provides novel and improved protein purification processes which incorporate certain types of carbonaceous materials and result in effective and selective removal of certain undesirable impurities without adversely effecting the yield of the desired protein product.1. A method of selectively remov... | 1,600 |
1,333 | 1,333 | 14,705,150 | 1,637 | This disclosure describes kits, reagents and methods for Recombinase Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The dis... | 1-39. (canceled) 40. A frieze dried pellet for a recombinase polymerase amplification process of DNA amplification of a target nucleic acid molecule, comprising: trehalose, and wherein said pellet does not contain polyethylene glycol. 41. The frieze dried pellet of claim 40, wherein said pellet comprises 2.5%-7.5% weig... | This disclosure describes kits, reagents and methods for Recombinase Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The dis... | 1,600 |
1,334 | 1,334 | 16,796,940 | 1,654 | The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 1-13. (canceled) 14. A method of treating hypertrophic cardiomyopathy in a mammalian subject, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2. 15. The method of claim 14, wherein the subject is suffering from heart failure. 1... | The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.1-13. (canceled) 14. A method of treating hypertrophic cardiomyopathy in a mammalian subject, ... | 1,600 |
1,335 | 1,335 | 15,684,226 | 1,612 | An oral care composition comprising zinc phosphate, stannous fluoride and a salicylamide, as well as methods of using the same. | 1. A high water oral care composition comprising an orally acceptable carrier, zinc phosphate, stannous fluoride, and a salicylamide. 2. The composition of claim 1, wherein the salicylamide is a non-halogenated salicylamide. 3. The composition of claim 2, wherein the salicylamide has the formula:
wherein R1 a... | An oral care composition comprising zinc phosphate, stannous fluoride and a salicylamide, as well as methods of using the same.1. A high water oral care composition comprising an orally acceptable carrier, zinc phosphate, stannous fluoride, and a salicylamide. 2. The composition of claim 1, wherein the salicylamide is ... | 1,600 |
1,336 | 1,336 | 15,789,716 | 1,612 | The present invention provides an aqueous oral rinse composition which includes zinc chloride, sorbitol, one or more pyrophosphates, and water. Methods of providing such an oral rinse composition are also provided herein. | 1. An oral rinse composition comprising:
zinc chloride; water, wherein the amount of water present in the composition is at least about 80%, based on the total weight of the composition; one or more sugar alcohols; and optionally, one or more pyrophosphates; wherein the oral rinse composition is substantially free of o... | The present invention provides an aqueous oral rinse composition which includes zinc chloride, sorbitol, one or more pyrophosphates, and water. Methods of providing such an oral rinse composition are also provided herein.1. An oral rinse composition comprising:
zinc chloride; water, wherein the amount of water present ... | 1,600 |
1,337 | 1,337 | 15,102,572 | 1,612 | Disclosed is a dental bleaching gel composition with high electric conductivity. It was the object of the present invention to provide a bleaching gel composition that is less initating than prior art gels, and is highly efficient such that it can bleach within shorter time. The composition includes a peroxide, or a pe... | 1. A dental bleaching gel composition comprising:
a peroxide or peroxide releasing compound, a cross-linked polyacrylate polymer, an aqueous vehicle; and at least one electrical conductivity enhancing ingredient; wherein the electrical conductivity of the gel is at least 250 microsiemens/cm. 2. The dental bleaching gel... | Disclosed is a dental bleaching gel composition with high electric conductivity. It was the object of the present invention to provide a bleaching gel composition that is less initating than prior art gels, and is highly efficient such that it can bleach within shorter time. The composition includes a peroxide, or a pe... | 1,600 |
1,338 | 1,338 | 16,226,804 | 1,654 | A histidine-free composition comprising: a high purity factor VIII (r-factor VIII); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor VIII; an amount of calcium chloride for specific stabilization of factor VIII. | 1. A cryo/lyo protected histidine-free composition comprising:
(a) a non-native purified recombinant factor VIII (r-factor VIII); (b) 3-15 mg/ml arginine and 3-15 mg/ml sucrose combined as cryo/lyoprotectant, and 10-40 mg/ml sodium chloride as a bulking agent; (c) a surface-active agent in a concentration effective to ... | A histidine-free composition comprising: a high purity factor VIII (r-factor VIII); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor VIII; an amount of calcium chloride for specific stabilization of factor VIII.1. A cryo/lyo protected histidine-free composition... | 1,600 |
1,339 | 1,339 | 15,631,003 | 1,612 | This invention relates to oral care compositions comprising a first source of stannous, a second source of stannous, wherein the second source of stannous contains stannous pyrophosphate, and a zinc source selected from the group consisting of: zinc oxide, zinc citrate, zinc lactate, and combinations thereof, as well a... | 1. An oral care composition comprising:
a zinc source selected from the group consisting of: zinc oxide, zinc citrate, zinc lactate, and combinations thereof; a first source of stannous; and a second source of stannous, wherein the second source of stannous comprises stannous pyrophosphate. 2. The oral care composition... | This invention relates to oral care compositions comprising a first source of stannous, a second source of stannous, wherein the second source of stannous contains stannous pyrophosphate, and a zinc source selected from the group consisting of: zinc oxide, zinc citrate, zinc lactate, and combinations thereof, as well a... | 1,600 |
1,340 | 1,340 | 14,367,635 | 1,634 | The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit compris... | 1. A method for the in vitro diagnosis or prognosis of prostate cancer in a biological sample taken from a patient, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said nucleic acid sequences being chosen from the sequences identified in SEQ ID N... | The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit compris... | 1,600 |
1,341 | 1,341 | 15,876,892 | 1,644 | Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral toleranc... | 1-35. (canceled) 36. A method for treating mucopolysaccharidosis type IVA in a subject suffering from mucopolysaccharidosis type IVA, the method comprising: administering to the subject an effective amount of a polypeptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID ... | Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral toleranc... | 1,600 |
1,342 | 1,342 | 16,002,199 | 1,617 | The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophil... | 1. A process for preparing a solid dosage form, the process comprising:
a) blending at least one active pharmaceutical ingredient (API) or pharmaceutically acceptable salt thereof, at least one natural gum, a combination of hydrophilic gelling polymers, and an effervescent system to form a mixture; b) forming the mixtu... | The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophil... | 1,600 |
1,343 | 1,343 | 14,964,868 | 1,653 | An apparatus for perfusing an organ or tissue includes a perfusion circuit for perfusing the organ or tissue; an oxygenator for oxygenating perfusate that circulates through the perfusion circuit; and an oxygen supply device such as an oxygen concentrator or an oxygen generator configured to supply oxygen to the oxygen... | 1. An apparatus for perfusing an organ or tissue, the apparatus comprising:
a perfusion circuit configured to perfuse the organ or tissue with liquid perfusate; an oxygenator connected to the perfusion circuit; and an oxygen supply device configured to supply produced oxygen to the oxygenator, wherein the oxygenator is... | An apparatus for perfusing an organ or tissue includes a perfusion circuit for perfusing the organ or tissue; an oxygenator for oxygenating perfusate that circulates through the perfusion circuit; and an oxygen supply device such as an oxygen concentrator or an oxygen generator configured to supply oxygen to the oxygen... | 1,600 |
1,344 | 1,344 | 14,441,311 | 1,619 | The present invention relates to a cosmetic composition, in particular a hair composition, comprising i) one or more dicarbonyl compounds corresponding to formula (I) below, and/or derivatives thereof and/or hydrates thereof and/or salts thereof: in which formula (I): R represents an atom or group chosen from i) hydrog... | 1. Process for straightening keratin fibres such as the hair, which comprises the application to the said fibres of a cosmetic composition comprising:
i) one or more dicarbonyl compounds corresponding to formula (I) below, and/or derivatives thereof and/or hydrates thereof and/or salts thereof:
in which for... | The present invention relates to a cosmetic composition, in particular a hair composition, comprising i) one or more dicarbonyl compounds corresponding to formula (I) below, and/or derivatives thereof and/or hydrates thereof and/or salts thereof: in which formula (I): R represents an atom or group chosen from i) hydrog... | 1,600 |
1,345 | 1,345 | 15,512,322 | 1,612 | Provided is an antimicrobial coating material comprising one or more biocides encapsulated in inorganic-organic shells. The antimicrobial coating material can be applied on porous materials or porous media to form and antimicrobial coating without changing the physical properties and the functions of porous materials o... | 1. An antimicrobial coating material for surface coating comprising of:
(a) biocides comprising at least one antimicrobial component selected from the group consisting of chlorine dioxide, hydrogen peroxide, peroxy acids, alcoholic compounds, phenolic compounds, essential oils, antimicrobial components of essential oil... | Provided is an antimicrobial coating material comprising one or more biocides encapsulated in inorganic-organic shells. The antimicrobial coating material can be applied on porous materials or porous media to form and antimicrobial coating without changing the physical properties and the functions of porous materials o... | 1,600 |
1,346 | 1,346 | 14,770,873 | 1,613 | Microcapsules comprised of a core comprising one or more sunscreen agents and a shell of a wall-forming polymeric material, which are non-rupturable upon rubbing or pressing on the skin, and processes of preparing same are disclosed. Topical formulations comprising the microcapsules, which can be, for example, sunscree... | 1. A microcapsule comprising a core comprising at least one sunscreen agent and a shell enveloping the core, the shell being comprised of a wall-forming polymeric material comprising at least one polymer or copolymer selected from the group consisting of a polyacrylate, a polymethacrylate, a cellulose ether, a cellulos... | Microcapsules comprised of a core comprising one or more sunscreen agents and a shell of a wall-forming polymeric material, which are non-rupturable upon rubbing or pressing on the skin, and processes of preparing same are disclosed. Topical formulations comprising the microcapsules, which can be, for example, sunscree... | 1,600 |
1,347 | 1,347 | 14,399,157 | 1,644 | There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure... | 1. A method of treating an inflammatory response to infection, the method comprising: administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject in need thereof. 2. The method of claim 1, wherein the PCSK9 inhibitor is an antibody or antigen-binding fragment thereof. 3. The method of claim ... | There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure... | 1,600 |
1,348 | 1,348 | 14,925,043 | 1,618 | A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose... | 1. A method of treating one or more of symptoms selected from the group consisting of pain, headache, fever, nasal congestion, sinus congestion, runny nose, myalgia, ear fullness, otic barotrauma, said method comprising administering to a mammalian subject in need thereof as a single dosage form a pharmaceutical compos... | A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose... | 1,600 |
1,349 | 1,349 | 16,013,594 | 1,629 | This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an anionic surfactant, and to methods of using and of making such compositions. | 1-41. (canceled) 42. A method of reducing the adhesion of bacteria to tooth surfaces in an oral cavity of a subject, the method comprising treating the oral cavity with an oral care composition comprising a basic amino acid, in free or salt form, and an anionic surfactant. 43. A method according to claim 42, wherein th... | This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an anionic surfactant, and to methods of using and of making such compositions.1-41. (canceled) 42. A method of reducing the adhesion of bacteria to tooth surfaces in an oral cavity ... | 1,600 |
1,350 | 1,350 | 14,367,526 | 1,634 | The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least o... | 1. A method for the in vitro diagnosis or prognosis of colon cancer in a biological sample taken from a patient, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said nucleic acid sequences being chosen from the sequences identified in SEQ ID NOs:... | The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least o... | 1,600 |
1,351 | 1,351 | 14,367,673 | 1,634 | The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker o... | 1. A method for the in vitro diagnosis or prognosis of testicular cancer in a biological sample taken from a patient, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said nucleic acid sequences being chosen from the sequences identified in SEQ ID... | The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker o... | 1,600 |
1,352 | 1,352 | 13,543,194 | 1,619 | Aerosol compositions propelled by compressed gas providing enhanced intensity of one or more active components (e.g., fragrance, malodor counteractant, insecticide, disinfectant, or antimicrobial) over an extended period of time in the environment of use consistently over the life of the product. This is provided by a ... | 1. An aerosol article comprising
(a) a composition comprising
(i) at least one compressed gas propellant;
(ii) about 0.1 to about 2.5 wt. % of at least one active ingredient;
(iii) water as a solvent carrier and in an amount to serve as a major component of said composition;
wherein said composition has a volatile org... | Aerosol compositions propelled by compressed gas providing enhanced intensity of one or more active components (e.g., fragrance, malodor counteractant, insecticide, disinfectant, or antimicrobial) over an extended period of time in the environment of use consistently over the life of the product. This is provided by a ... | 1,600 |
1,353 | 1,353 | 16,117,857 | 1,644 | Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limit... | 1. A method for detecting a cell that produces an antibody against a CNS-specific antigen, comprising the steps:
a) providing a cell culture well having a surface and a cell culture medium therein; b) attaching a CNS-specific antigen to said surface; c) introducing a sample of peripheral blood mononuclear cells (PBMCs)... | Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limit... | 1,600 |
1,354 | 1,354 | 14,217,070 | 1,633 | Compositions can be used to stimulate growth of a hair shaft from a hair follicle. These compositions can include methylated polynucleotides useful in treatment of autoimmune diseases or conditions, including those, such as alopecia areata, that result in hair loss. | 1. A method of stimulating growth of a hair shaft from a hair follicle, comprising:
administering to a subject in need thereof an effective amount of a polynucleotide, wherein said polynucleotide comprises a sequence that encodes a pro-apoptotic protein, or a functional fragment thereof, and wherein the methylation lev... | Compositions can be used to stimulate growth of a hair shaft from a hair follicle. These compositions can include methylated polynucleotides useful in treatment of autoimmune diseases or conditions, including those, such as alopecia areata, that result in hair loss.1. A method of stimulating growth of a hair shaft from... | 1,600 |
1,355 | 1,355 | 16,012,508 | 1,613 | Antimicrobial compositions for killing or deactivating microbes, such as viruses, bacteria, or fungi, include metal nanoparticles, a carrier, and a plurality of metal nanoparticles. The nanoparticles can be selected to have a particle size and particle size distribution to selectively and preferentially kill one of a v... | 1. A method of selectively killing or deactivating a target microbe, comprising:
applying an antimicrobial composition to the target microbe or to a substrate containing the target microbe, the antimicrobial composition comprising:
a carrier; and
a plurality of spherical-shaped, nonionic metal nanoparticles formed by l... | Antimicrobial compositions for killing or deactivating microbes, such as viruses, bacteria, or fungi, include metal nanoparticles, a carrier, and a plurality of metal nanoparticles. The nanoparticles can be selected to have a particle size and particle size distribution to selectively and preferentially kill one of a v... | 1,600 |
1,356 | 1,356 | 13,899,090 | 1,619 | In accordance with one aspect, embolic particles are provided that comprise a biodegradable polymer and a therapeutic agent, wherein the particles are configured such that, upon administration to a body lumen of a subject, the therapeutic agent is released from the time of administration up until a first point in time ... | 1. An embolic particle comprising a biodegradable polymer and a therapeutic agent, wherein the particle is configured such that, upon administration to an body lumen of a subject, the therapeutic agent is released from the time of administration up until a first point in time that ranges anywhere from about 1 week afte... | In accordance with one aspect, embolic particles are provided that comprise a biodegradable polymer and a therapeutic agent, wherein the particles are configured such that, upon administration to a body lumen of a subject, the therapeutic agent is released from the time of administration up until a first point in time ... | 1,600 |
1,357 | 1,357 | 13,980,418 | 1,619 | The present invention relates to a cosmetic composition for eyelashes such as a mascara, comprising: at least one anionic surfactant including 2-amino-2-methyl-1,3-propanediol in combination with a C 16 -C 24 fatty acid; and at least one film-forming polymer present in the form of particles dispersed in an aqueous pha... | 1.-15. (canceled) 16. A cosmetic composition for eyelashes, comprising:
at least one anionic surfactant comprising 2-amino-2-methyl-1,3-propanediol in combination with at least one C16-C24 fatty acid; and at least one film-forming polymer present in the form of particles dispersed in an aqueous phase, wherein the weigh... | The present invention relates to a cosmetic composition for eyelashes such as a mascara, comprising: at least one anionic surfactant including 2-amino-2-methyl-1,3-propanediol in combination with a C 16 -C 24 fatty acid; and at least one film-forming polymer present in the form of particles dispersed in an aqueous pha... | 1,600 |
1,358 | 1,358 | 14,999,688 | 1,611 | A fragrance slurry pad patterned sampler including a base material applied to one of coated and uncoated paper, flexible film and paper laminations, aluminum foil, thermal plastics, PET, OPP, BOPP, EVA, PE, and other commonly polymer films providing the base for the fragrance sampler, the sampler including a slurry for... | 1. A fragrant slurry pad patterned sampler including a substrate, a microencapsulated fragrance material applied to said substrate, fragrance material having discrete patterned applications to the substrate, said fragrance material comprised of select aroma chemicals, at least two portions of the fragrance material app... | A fragrance slurry pad patterned sampler including a base material applied to one of coated and uncoated paper, flexible film and paper laminations, aluminum foil, thermal plastics, PET, OPP, BOPP, EVA, PE, and other commonly polymer films providing the base for the fragrance sampler, the sampler including a slurry for... | 1,600 |
1,359 | 1,359 | 15,561,130 | 1,649 | This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at l... | 1. An immunogen comprising:
an antigen presentation component; and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. 2. The immunogen of claim 1 wherein the MAPT component comprises at least one amino acid residue modified to comprise a PO3H2 group... | This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at l... | 1,600 |
1,360 | 1,360 | 15,294,869 | 1,617 | The present invention provides novel insecticidal formulations comprising an effective concentration of: 1) at least one or more essential oils and an insecticidal soap; 2) at least one or more essential oils, an insecticidal soap, and pyrethrins; 3) at least one or more essential oils and pyrethrins; 4) at least one o... | 1-39. (canceled) 40: An insecticidal composition comprising neem oil, pyrethrins, and an antioxidant selected from the group consisting of ethoxyquin, a tocopherol, and BHT. 41: The insecticidal composition of claim 40, wherein the amount of neem oil is about 0.25% to about 12% by weight, the amount of pyrethrins is ab... | The present invention provides novel insecticidal formulations comprising an effective concentration of: 1) at least one or more essential oils and an insecticidal soap; 2) at least one or more essential oils, an insecticidal soap, and pyrethrins; 3) at least one or more essential oils and pyrethrins; 4) at least one o... | 1,600 |
1,361 | 1,361 | 13,824,533 | 1,613 | A cosmetic composition includes, in a physiologically acceptable medium: at least water, at least alkylcellulose, at least one first hydrocarbon-based non-volatile oil, chosen from: C10-C26 alcohols, preferably monoalcohols; optionally hydroxylated monoesters, diesters or triesters of a C2-C8 monocarboxylic or polycarb... | 1. Cosmetic composition comprising, in a physiologically acceptable medium:
at least 5% by weight of water; at least alkylcellulose, the alkyl residue of which comprises between 1 and 6 carbon atoms; at least one first hydrocarbon-based non-volatile oil, chosen from: C10-C26 alcohols, optionally hydroxylated monoesters... | A cosmetic composition includes, in a physiologically acceptable medium: at least water, at least alkylcellulose, at least one first hydrocarbon-based non-volatile oil, chosen from: C10-C26 alcohols, preferably monoalcohols; optionally hydroxylated monoesters, diesters or triesters of a C2-C8 monocarboxylic or polycarb... | 1,600 |
1,362 | 1,362 | 14,841,898 | 1,619 | Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol. | 1. A modified release formulation of mazindol comprising mazindol as an active pharmaceutical ingredient, at least one release controlling polymer selected from pH-dependent polymers and pH-independent polymers, and at least one pharmaceutically acceptable excipient, wherein the total amount of water in the formulation... | Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol.1. A modified release formulation of mazindol comprising mazindol as an active pharmaceutical ingredient, at least one rel... | 1,600 |
1,363 | 1,363 | 16,228,996 | 1,612 | Disclosed is an anhydrous makeup removing composition and method for removing making using such a composition. The composition includes at least two esters having a molecular weight less than 350 g/mol and a polarity index of less than or equal to 24.2 mN/m, where the composition contains less than 5 w/w % of any ester... | 1. An anhydrous makeup removing composition, comprising:
at least three esters having a molecular weight less than 350 g/mol and a polarity index of less than or equal to 24.2 mN/m, wherein the composition contains less than 5 w/w % of any esters having molecular weights greater than 350 g/mol or having a polarity inde... | Disclosed is an anhydrous makeup removing composition and method for removing making using such a composition. The composition includes at least two esters having a molecular weight less than 350 g/mol and a polarity index of less than or equal to 24.2 mN/m, where the composition contains less than 5 w/w % of any ester... | 1,600 |
1,364 | 1,364 | 13,490,852 | 1,631 | Methods for ex vivo perfusion of organs (and/or tissues) with a perfusate designed to condition the organ with the desired effect being that upon transplant, said organ, having been administered said perfusate, is less likely to experience delayed graft function, deleterious effects of ischemia/reperfusion injury, incl... | 1. A method of determining parameters for maintaining viability of at least one organ in at least one device selected from an organ transporter, perfusion apparatus, cassette, and organ diagnostic apparatus, the method comprising:
forming a data record by uploading to a processor compiled data comprising:
data relating... | Methods for ex vivo perfusion of organs (and/or tissues) with a perfusate designed to condition the organ with the desired effect being that upon transplant, said organ, having been administered said perfusate, is less likely to experience delayed graft function, deleterious effects of ischemia/reperfusion injury, incl... | 1,600 |
1,365 | 1,365 | 14,229,624 | 1,612 | L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives an... | 1. A non-human primate model of a neurodegnerative disease, wherein the model is produced by administration of BMAA to the non-human primate. 2. The non-human primate model of claim 1, wherein the non-human primate is a vervet. 3. The non-human primate of claim 1, wherein the neurodegnerative disease comprises Alzheime... | L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives an... | 1,600 |
1,366 | 1,366 | 15,772,846 | 1,616 | The invention relates to a cosmetic foam of a) an emulsion containing a combination of sodium cetearyl sulfate and glyceryl monostearate SE and b) a gas or gas mixture of propane, n-butane and/or isobutane, foaming the emulsion, the emulsion being free of polyethylene glycol derivatives (PEG derivatives). | 1.-17. (canceled) 18. A cosmetic foam, wherein the foam comprises
(i) an emulsion comprising (a) sodium cetearyl sulfate and (b) glyceryl monostearate SE and (ii) a gas or gas mixture of propane, n-butane and/or isobutane which foams the emulsion; and wherein (i) is free of polyethylene glycol derivatives (PEG derivati... | The invention relates to a cosmetic foam of a) an emulsion containing a combination of sodium cetearyl sulfate and glyceryl monostearate SE and b) a gas or gas mixture of propane, n-butane and/or isobutane, foaming the emulsion, the emulsion being free of polyethylene glycol derivatives (PEG derivatives).1.-17. (cancel... | 1,600 |
1,367 | 1,367 | 14,367,608 | 1,634 | The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit includin... | 1. A method for the in vitro diagnosis or prognosis of ovarian cancer in a biological sample taken from a patient, which comprises a step of detecting at least two expression products respectively of at least two nucleic acid sequences, said nucleic acid sequences being chosen from the sequences identified in SEQ ID NO... | The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit includin... | 1,600 |
1,368 | 1,368 | 14,415,894 | 1,619 | The present invention relates to a cosmetic composition for coating keratinous fibres of the emulsion type, comprising: an aqueous phase, at least one wax, an emulsifying system comprising at least one surfactant, at least one film-forming polymer present in a solids content of greater than or equal to 5% by weight, wi... | 1. A cosmetic composition of an emulsion type, comprising:
an aqueous phase, a wax, an emulsifying system comprising a non-ionic surfactant exhibiting, at 25° C., an HLB balance within a Griffin meaning of greater than or equal to 8, a film-forming polymer present in a solids content of greater than or equal to 5% by w... | The present invention relates to a cosmetic composition for coating keratinous fibres of the emulsion type, comprising: an aqueous phase, at least one wax, an emulsifying system comprising at least one surfactant, at least one film-forming polymer present in a solids content of greater than or equal to 5% by weight, wi... | 1,600 |
1,369 | 1,369 | 15,015,968 | 1,662 | Methods and compositions for plastid transformation and regeneration or development of transplastomic plants are provided. Embryo explants may be excised from seeds, and their meristematic tissue may be transformed directly without initiation of any callus phase before and/or after transformation. The present methods m... | 1. A method of transforming a plant plastid, comprising the steps of:
(a) preparing an explant from a seed of a plant, the explant comprising meristematic tissue of an embryo of the seed; and (b) transforming at least one plastid of a cell of the explant with an exogenous DNA molecule, the exogenous DNA molecule compri... | Methods and compositions for plastid transformation and regeneration or development of transplastomic plants are provided. Embryo explants may be excised from seeds, and their meristematic tissue may be transformed directly without initiation of any callus phase before and/or after transformation. The present methods m... | 1,600 |
1,370 | 1,370 | 16,049,310 | 1,611 | The instant disclosure relates to methods for treating skin, for example, methods for desquamation of the skin of the face. The methods use a two-step process of first treating the skin with an alkaline composition having a pH of at least 8 followed by a second step of treating the skin with an acidic composition havin... | 1. A method for treating skin comprising:
(a) applying an alkaline composition having a pH of at least 8 to the skin and allowing it to remain on the skin for a first period of time of at least 30 seconds, the alkaline composition comprising:
(i) about 0.05 to about 25 wt. %, based on the total weight of the alkaline c... | The instant disclosure relates to methods for treating skin, for example, methods for desquamation of the skin of the face. The methods use a two-step process of first treating the skin with an alkaline composition having a pH of at least 8 followed by a second step of treating the skin with an acidic composition havin... | 1,600 |
1,371 | 1,371 | 14,994,169 | 1,619 | A capsule with a shell and a fill phase. The fill phase contains less than about 5% beeswax by weight of the capsule and a supercritical extract of an herb. The capsule can be both vegetarian and meet the non-GMO Project Standard. | 1. A capsule comprising:
a. a shell; b. a fill phase comprising beeswax, candelilla wax, and a supercritical extract of an herb;
wherein the capsule is vegetarian and meets the non-GMO Project Standards;
wherein the capsule comprises greater than 0% and less than about 5%, by weight of the capsule, beeswax; and
wherei... | A capsule with a shell and a fill phase. The fill phase contains less than about 5% beeswax by weight of the capsule and a supercritical extract of an herb. The capsule can be both vegetarian and meet the non-GMO Project Standard.1. A capsule comprising:
a. a shell; b. a fill phase comprising beeswax, candelilla wax, a... | 1,600 |
1,372 | 1,372 | 15,345,991 | 1,653 | An organ perfusion system comprises: a perfusion fluid circuit ( 16 ) arranged to circulate perfusion fluid through the organ; a surrogate organ ( 126 ) arranged to be connected into the circuit in place of the organ so that the circuit can circulate fluid through the surrogate organ; and organ sensing means arranged t... | 1. A method of operating a perfusion system to perfuse a bodily organ, the method comprising:
providing a perfusion system, the system comprising a perfusion fluid circuit arranged to circulate perfusion fluid through the bodily organ, a surrogate organ arranged to be connected into the circuit in place of the bodily o... | An organ perfusion system comprises: a perfusion fluid circuit ( 16 ) arranged to circulate perfusion fluid through the organ; a surrogate organ ( 126 ) arranged to be connected into the circuit in place of the organ so that the circuit can circulate fluid through the surrogate organ; and organ sensing means arranged t... | 1,600 |
1,373 | 1,373 | 13,186,017 | 1,649 | A laboratory method for screening, diagnosing, monitoring and/or staging early onset Alzheimer's disease which consists of mild cognitive impairment entails conducting a blood test after an oxidative exposure of serum to assay for the presence of an elevated level of redox-reactive autoantibodies. | 1. A laboratory method for screening, diagnosing, monitoring and/or staging early onset Alzheimer's disease which consists of mild cognitive impairment comprises conducting a blood test after an oxidative exposure of serum to assay for the presence of an elevated level of redox-reactive autoantibodies. 2. The method of... | A laboratory method for screening, diagnosing, monitoring and/or staging early onset Alzheimer's disease which consists of mild cognitive impairment entails conducting a blood test after an oxidative exposure of serum to assay for the presence of an elevated level of redox-reactive autoantibodies.1. A laboratory method... | 1,600 |
1,374 | 1,374 | 15,821,146 | 1,642 | The present invention provides a novel cancer marker for testing a morbidity risk of a cancer. The cancer marker according to the present invention is a prorenin receptor. A test method for testing a morbidity risk of a cancer according to the present invention includes measuring a prorenin receptor expression in a bio... | 1. A test and therapeutic method, comprising:
measuring a prorenin receptor expression level in a biological specimen obtained from a subject, wherein
the biological specimen is a blood specimen, and
a cancer to be tested is at least one of a pancreatic cancer and a brain tumor;
comparing the prorenin receptor express... | The present invention provides a novel cancer marker for testing a morbidity risk of a cancer. The cancer marker according to the present invention is a prorenin receptor. A test method for testing a morbidity risk of a cancer according to the present invention includes measuring a prorenin receptor expression in a bio... | 1,600 |
1,375 | 1,375 | 16,267,301 | 1,618 | The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detect... | 1. A method for treating and/or preventing a disease or condition associated with the accumulation and/or aggregation of Aβ peptide in neural tissue, or for treating and/or preventing a disorder or condition associated with Down's syndrome, or for treating and/or preventing a post-traumatic stress disorder or condition... | The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detect... | 1,600 |
1,376 | 1,376 | 14,315,140 | 1,637 | In some embodiments, the present teachings provide compositions, systems, methods and kits for generating a population of nucleic acid fragments. In some embodiments, nucleic acids can be fragmented enzymatically. For example, methods for generating a population of nucleic acid fragments can include a nucleic acid nick... | 1. A method for generating a population of nucleic acid fragments comprising:
(a) nicking a double stranded nucleic acid molecule at least once on each strand, wherein the nucleic acid molecule does not include uracil; and (b) fragmenting the nucleic acid molecule by nick translating at least one nick in each strand an... | In some embodiments, the present teachings provide compositions, systems, methods and kits for generating a population of nucleic acid fragments. In some embodiments, nucleic acids can be fragmented enzymatically. For example, methods for generating a population of nucleic acid fragments can include a nucleic acid nick... | 1,600 |
1,377 | 1,377 | 16,292,406 | 1,699 | The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia. | 1-56. (canceled) 57. A compound of Formula (II):
wherein
X is selected from a covalent bond, S, or O;
Y is S or O;
- - - - -W- - - - - represents a group selected from —CH═, —CH2—, —CH2—CH2—, —CH2—CH═, and —CH═CH—;
Z is selected from O, CH, and CH2, provided when Y is O, Z is O;
R1 and R2 are independently s... | The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.1-56. (canceled) 57. A compound of Formula (II):
wherein
X is selected from a coval... | 1,600 |
1,378 | 1,378 | 15,873,284 | 1,615 | A hand powder composition, particularly useful for musicians of necked stringed instruments, comprising a fine moisture absorbing powder in an amount from about 90%-99% by weight of the total composition and a fine polytetrafluoroethylene powder in an amount from about 1%-7% by weight of the total composition. The poly... | 1. A hand powder composition comprising: a fine moisture absorbing powder in an amount from about 90%-99% by weight of the total composition; and
a fine polytetrafluoroethylene powder in an amount from about 1%-7% by weight of the total composition. 2. The hand powder composition of claim 1 wherein the average particle... | A hand powder composition, particularly useful for musicians of necked stringed instruments, comprising a fine moisture absorbing powder in an amount from about 90%-99% by weight of the total composition and a fine polytetrafluoroethylene powder in an amount from about 1%-7% by weight of the total composition. The poly... | 1,600 |
1,379 | 1,379 | 15,516,038 | 1,651 | According to the invention, it has been found that a particulate biomass containing an oxidation-sensitive material of value can be converted into a particularly easy-to-handle product in a gentle manner if it is subjected to a granulation with the addition of an agglomeration auxiliary. | 1-17. (canceled) 18. A method for producing a particulate biomass having an oxidation-sensitive material of value, said method comprising granulating a particulate starting biomass in the presence of an agglomeration auxiliary. 19. The method of claim 18, wherein carbohydrates, or modified carbohydrates, are used as th... | According to the invention, it has been found that a particulate biomass containing an oxidation-sensitive material of value can be converted into a particularly easy-to-handle product in a gentle manner if it is subjected to a granulation with the addition of an agglomeration auxiliary.1-17. (canceled) 18. A method fo... | 1,600 |
1,380 | 1,380 | 14,414,326 | 1,639 | The present invention relates to complexes of oligonucleotide-encoded libraries and methods of tagging and using such libraries. In particular, the oligonucleotides and methods can include complexes having at least one linkage for which a polymerase has reduced ability to read or translocate through. | 1. A complex comprising:
(i) a chemical entity comprising one or more scaffolds or one or more building blocks; (ii) a first oligonucleotide tag encoding the identity of at least one of said one or more scaffolds or building blocks; and (iii) a headpiece having a first functional group and a second functional group, wh... | The present invention relates to complexes of oligonucleotide-encoded libraries and methods of tagging and using such libraries. In particular, the oligonucleotides and methods can include complexes having at least one linkage for which a polymerase has reduced ability to read or translocate through.1. A complex compri... | 1,600 |
1,381 | 1,381 | 14,923,430 | 1,618 | A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that rel... | 1-28. (canceled) 29. A method for treating a wound of a patient in need thereof, said method comprising:
(a) providing a polyvinyl alcohol (PVA) foam article comprised of PVA foam, which has a density of at least 0.074 g/cm3 before complexing with iodine, and iodine complexed at least in part to the PVA foam; and (b) a... | A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that rel... | 1,600 |
1,382 | 1,382 | 15,753,497 | 1,617 | A personal care conditioning and/or styling synergistic composition for a keratin substrate comprising: (i) about 0.1 wt. % to about 20 wt. % of PolyAPTAC polymer; (ii) about 0.1 wt. % to about 5 wt. % of Polyquaternium-37; (iii) about 0.1 wt. % to about 5 wt. % of at least one cationic surfactants; (iv) about 0.1 wt. ... | 1. A personal care conditioning and/or styling synergistic composition for a keratin substrate comprising:
i. about 0.1 wt. % to about 20 wt. % of PolyAPTAC polymer; ii. about 0.1 wt. % to about 5 wt. % of Polyquaternium-37; iii. about 0.1 wt. % to about 5 wt. % of at least one cationic surfactants; iv. about 0.1 wt. %... | A personal care conditioning and/or styling synergistic composition for a keratin substrate comprising: (i) about 0.1 wt. % to about 20 wt. % of PolyAPTAC polymer; (ii) about 0.1 wt. % to about 5 wt. % of Polyquaternium-37; (iii) about 0.1 wt. % to about 5 wt. % of at least one cationic surfactants; (iv) about 0.1 wt. ... | 1,600 |
1,383 | 1,383 | 15,553,267 | 1,617 | The invention relates to a plant protection and/or plant growth promotion system, comprising at least one anchor peptide for increased binding to a plant part, a support function, which is indirectly or directly bound to the anchor peptide, and an active substance for protecting the plant and/or promoting plant growth ... | 1. A plant protection and/or plant growth promotion system, comprising at least one anchor peptide for increased binding to a plant organ or a plant part, a support function, which is indirectly or directly bound to the anchor peptide, and an active substance for protecting the plant and/or promoting plant growth and/o... | The invention relates to a plant protection and/or plant growth promotion system, comprising at least one anchor peptide for increased binding to a plant part, a support function, which is indirectly or directly bound to the anchor peptide, and an active substance for protecting the plant and/or promoting plant growth ... | 1,600 |
1,384 | 1,384 | 14,367,872 | 1,634 | The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marke... | 1. A method for the in vitro diagnosis or prognosis of lung cancer in a biological sample taken from a patient, which comprises a step of detecting at least one expression product of at least one nucleic acid sequence, said nucleic acid sequence being chosen from the sequences identified in SEQ ID NOs: 1 to 242 or from... | The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marke... | 1,600 |
1,385 | 1,385 | 14,428,057 | 1,617 | The present application is directed to a system and device for attraction of pests. This system comprises CO 2 -releasing microorganisms, and also nutrients specific to these microorganisms, and this system, or the device, comprises one or more biodegradable biopolymers and allows CO 2 , and optionally other attractant... | 1. A system or device for attracting pests, comprising
CO2-releasing microorganisms and nutrients specific for these microorganisms, and one or more biodegradable biopolymers which fully surround other constituents of the system and which allow release of CO2 over a period of more than 20 days. 2. The system or device ... | The present application is directed to a system and device for attraction of pests. This system comprises CO 2 -releasing microorganisms, and also nutrients specific to these microorganisms, and this system, or the device, comprises one or more biodegradable biopolymers and allows CO 2 , and optionally other attractant... | 1,600 |
1,386 | 1,386 | 14,422,868 | 1,619 | The invention relates to a cosmetic composition comprising a blue dye powder containing an anthocyan, a metal ion and tannic acid and a cosmetic additive. The invention also relates to a process for making up keratin materials by applying the cosmetic composition to the keratin materials. | 1. Process for making up keratin materials, comprising the application to the keratin materials of a dye powder having a blue colour comprising at least one anthocyan, metal ions chosen from the group of ions derived from Al(III), Ca(II), Cu(II), Fe(II), Fe(III), Mg(II), Mn(II) and Zn(II) and mixtures thereof, tannic a... | The invention relates to a cosmetic composition comprising a blue dye powder containing an anthocyan, a metal ion and tannic acid and a cosmetic additive. The invention also relates to a process for making up keratin materials by applying the cosmetic composition to the keratin materials.1. Process for making up kerati... | 1,600 |
1,387 | 1,387 | 14,381,366 | 1,634 | A method detects nucleic acid with high sensitivity even when the target nucleic acid is detected by sandwich hybridization using neither nucleic acid amplification nor a sensitization technique. The method includes sequentially or simultaneously bringing a target nucleic acid or fragmentation product thereof, a plural... | 1. A method of detecting a target nucleic acid comprising:
sequentially or simultaneously bringing a fragmentation product a target nucleic acid, a plurality of detection probes, and a capture probe immobilized on a support, into contact with each other to hybridize said capture probe with said fragmentation product sa... | A method detects nucleic acid with high sensitivity even when the target nucleic acid is detected by sandwich hybridization using neither nucleic acid amplification nor a sensitization technique. The method includes sequentially or simultaneously bringing a target nucleic acid or fragmentation product thereof, a plural... | 1,600 |
1,388 | 1,388 | 14,951,736 | 1,628 | The present invention provides compounds of Formula I:
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5. | 1. A compound represented by Formula I or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, or combination thereof:
wherein:
X is absent, —C(O)NH— or —NH—;
R1 is selected from the group consisting of:
1) Hydrogen;
2) Substituted or unsubstituted —C1-C8 alkyl;
3) Substituted or unsubs... | The present invention provides compounds of Formula I:
pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.1. A compou... | 1,600 |
1,389 | 1,389 | 14,249,259 | 1,642 | The present invention concerns a method for predicting the potential for aggressive growth and/or the risk to progress to high grade cancer for tumors in cell based detection procedures. In one aspect the invention concerns the detection of overexpression of cyclin-dependent kinase inhibitor gene products as a tool for... | 1. A method for predicting a potential for breast tumors for aggressive growth and/or a risk to progress to high grade cancer, comprising:
obtaining a breast tumor sample of a subject; measuring by a cell based detection procedure whether at least one single cell of the breast tumor sample simultaneously overexpresses ... | The present invention concerns a method for predicting the potential for aggressive growth and/or the risk to progress to high grade cancer for tumors in cell based detection procedures. In one aspect the invention concerns the detection of overexpression of cyclin-dependent kinase inhibitor gene products as a tool for... | 1,600 |
1,390 | 1,390 | 15,818,450 | 1,656 | Disclosed herein are biohybrid protein complexes capable of using light energy to photocatalyze the reduction of N 2 into NH 3 . Also provided are methods of using biohybrid protein complexes to enzymatically reduce N 2 to NH 3 using light rather than chemical energy as the driving force. These methods may also incl... | 1. A biohybrid complex, comprising a photoactive nanoparticle and an enzyme, wherein the photoactive nanoparticle produces electrons when exposed to light and the enzyme uses the electrons produced by the photoactive nanoparticle to catalyze an enzymatic reaction. 2. The biohybrid complex of claim 1, further comprising... | Disclosed herein are biohybrid protein complexes capable of using light energy to photocatalyze the reduction of N 2 into NH 3 . Also provided are methods of using biohybrid protein complexes to enzymatically reduce N 2 to NH 3 using light rather than chemical energy as the driving force. These methods may also incl... | 1,600 |
1,391 | 1,391 | 12,695,235 | 1,635 | Microorganisms are identified as present in a complex sample or mixed culture by acquiring a mass spectrum of the sample and comparing it to combination spectra, each of which is formed by combining at least two reference mass spectra of known microorganisms. Microorganisms corresponding to the reference spectra used t... | 1. A method for identifying microorganisms present in a sample, comprising:
(a) acquiring a mass spectrum of the sample; (b) comparing the sample mass spectrum to each of a plurality of reference mass spectra, wherein each reference mass spectrum is a mass spectrum of a known microorganism; (c) selecting as a best set ... | Microorganisms are identified as present in a complex sample or mixed culture by acquiring a mass spectrum of the sample and comparing it to combination spectra, each of which is formed by combining at least two reference mass spectra of known microorganisms. Microorganisms corresponding to the reference spectra used t... | 1,600 |
1,392 | 1,392 | 15,754,073 | 1,627 | The invention relates to biocidal mixtures comprising penflufen-containing polymer particles, copper compounds and specific alkanolamines and to the use thereof for protecting wood and wood products, and also to wood preservatives comprising biocidal mixtures and optionally further active ingredients. | 1. A biocidal mixture comprising:
penflufen-containing polymer particles, at least one alkanolamine selected from the group consisting of monoalkylmonoamines, monoalkyldiamines, dialkylamines and trialkylamines, substituted by one, two or three hydroxyl groups, and at least one copper compound or copper complexes of th... | The invention relates to biocidal mixtures comprising penflufen-containing polymer particles, copper compounds and specific alkanolamines and to the use thereof for protecting wood and wood products, and also to wood preservatives comprising biocidal mixtures and optionally further active ingredients.1. A biocidal mixt... | 1,600 |
1,393 | 1,393 | 15,339,990 | 1,627 | Antifibrinolytic agents/drugs are applied to the concussive area of a patient's brain to counter the activation of a fibrinolytic process in the concussive area. Various techniques are described for administering the antifibrinolytic agent. | 1. In a method of treating concussions, the improvement being the administration of an antifibrinolytic agent to the concussive area of the patient's brain to counter the activation of a fibrinolytic process in the concussive area. 2. The method of claim 1 wherein the antifibrinolytic agent is administered to the brain... | Antifibrinolytic agents/drugs are applied to the concussive area of a patient's brain to counter the activation of a fibrinolytic process in the concussive area. Various techniques are described for administering the antifibrinolytic agent.1. In a method of treating concussions, the improvement being the administration... | 1,600 |
1,394 | 1,394 | 14,388,057 | 1,634 | A method for generating an image of a region of interest in a biological sample comprising the steps of: generating a first image including the region of interest of the biological sample having undergone a first protocol but not a second protocol; and generating a second image including the region of interest of the b... | 1. A method of generating an image of a region of interest in a biological sample comprising the steps of:
1) generating a first image including said region of interest of said biological sample having undergone a first protocol but not a second protocol; and 2) generating a second image including said region of intere... | A method for generating an image of a region of interest in a biological sample comprising the steps of: generating a first image including the region of interest of the biological sample having undergone a first protocol but not a second protocol; and generating a second image including the region of interest of the b... | 1,600 |
1,395 | 1,395 | 13,387,971 | 1,627 | The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized ... | 1-73. (canceled) 74. Biodegradable poly(ethylene glycol) based water-insoluble hydrogel comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the... | The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized ... | 1,600 |
1,396 | 1,396 | 16,535,693 | 1,612 | A whitening composition, an oral care product including the whitening composition, and a method for whitening teeth are disclosed. The whitening composition may include an anhydrous component and an aqueous component. The anhydrous component may include a base gel and a chloroisocyanurate. The chloroisocyanurate may be... | 1. A whitening composition, comprising:
an anhydrous component comprising a base gel and a chloroisocyanurate, wherein the chloroisocyanurate is present in the anhydrous component in an amount of from about 0.01 weight % to about 30 weight %, based on a total weight of the anhydrous component; and an aqueous component ... | A whitening composition, an oral care product including the whitening composition, and a method for whitening teeth are disclosed. The whitening composition may include an anhydrous component and an aqueous component. The anhydrous component may include a base gel and a chloroisocyanurate. The chloroisocyanurate may be... | 1,600 |
1,397 | 1,397 | 14,886,946 | 1,653 | Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM. | 1. A method of treating a wound in an individual in need thereof, comprising: contacting a wound of the individual with an umbilical cord powder, or with an umbilical cord product from which water has not been removed. 2. The method of claim 1, wherein the umbilical cord powder or the umbilical cord product from which ... | Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.1. A method of treating a wound in an individual in need thereof, comprising: contacting a wound of the individual with an umbilical cord powder, or wi... | 1,600 |
1,398 | 1,398 | 15,586,652 | 1,618 | A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core tha... | 1. A composition comprising a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates, the individual particulates respectively having:
a core including an active ingredient combination of an L-carnitine and a nootropic substance; and a release controlling polymer over the ... | A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core tha... | 1,600 |
1,399 | 1,399 | 15,550,763 | 1,623 | An injectable device, comprising a hyaluronic acid-based composition, useful for long lasting facial sculpting and correction of facial features, for example, for augmenting and shaping the profile, including for example, the chin, jawline or the nose, in a human being is provided. Methods of treatment are also provide... | 1. A sterile composition, implantable subdermally or supraperiostially into the chin area, jawline or nose of a patient in need thereof, the composition comprising a crosslinked hyaluronic acid (HA) crosslinked with 1,4-butanediol diglycidyl ether (BDDE);
wherein a HA concentration of the composition is greater than 20... | An injectable device, comprising a hyaluronic acid-based composition, useful for long lasting facial sculpting and correction of facial features, for example, for augmenting and shaping the profile, including for example, the chin, jawline or the nose, in a human being is provided. Methods of treatment are also provide... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.